Nuvectis Pharma Inc. Common Stock (NVCT)
Stock · NASDAQ · Health Care
$18.6as of 10/16/2026
Price chart
Active signals
NVCT Signal Track Record
How signals performed across all stocks →What NVCT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | +0.7% | 54% | September 18, 2026 |
| Bollinger Band Breakout | 26 | -4.3% | 38% | August 19, 2026 |
| Bollinger Band Breakdown | 7 | -0.9% | 14% | September 25, 2026 |
| 200-Day Moving Average TouchActive now | 7 | +8.2% | 86% | December 31, 2025 |
| Any 20-session window (baseline) | +0.8% | 51% |
Computed by MarketWall from daily closing prices since November 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NVCT
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry P…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 16
- Website
- nuvectis.com/
Fundamentals
- 1-day range
- $19.88$21.26
- Market cap
- $613.51M
- P/E (trailing)
- —
- P/E (forward)
- -22.00
- EPS (trailing)
- $-1.20
- Dividend yield
- —
- Beta
- -0.24
- Avg. volume
- 214.3K
Forecasts
5 analyst ratings
Nuvectis Pharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NVCTNuvectis Pharma Inc. Common Stock$18.6▼ 1.74%Market cap $613.51MP/E —$5.55$29.28
- CBIOCrescent Biopharma Inc. Common Stock$11.84▼ 5.13%Market cap $610.27MP/E —$8.72$27.41
- MPLTMapLight Therapeutics Inc. Common Stock$7.7▼ 3.99%Market cap $602.19MP/E —$8.7$40.43
- FTHFaeth Therapeutics Inc. Common Stock$18.8▼ 8.74%Market cap $632.57MP/E —$13.43$42.14
- CRMDCorMedix Inc. Common Stock$7.26▼ 2.68%Market cap $589.17MP/E 3.08$6.13$13.02
- ALTAltimmune Inc. Common Stock$2.2▼ 6.78%Market cap $585.37MP/E —$2.56$6.44
- CTNMContineum Therapeutics Inc. Class A Common Stock$7.08▼ 10.38%Market cap $577.48MP/E —$7.96$17.79
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NVCT Nuvectis Pharma Inc. Common Stock | $613.51M | — | $18.6 | ▼ 1.74% | $5.55$29.28 |
| CBIO Crescent Biopharma Inc. Common Stock | $610.27M | — | $11.84 | ▼ 5.13% | $8.72$27.41 |
| MPLT MapLight Therapeutics Inc. Common Stock | $602.19M | — | $7.7 | ▼ 3.99% | $8.7$40.43 |
| FTH Faeth Therapeutics Inc. Common Stock | $632.57M | — | $18.8 | ▼ 8.74% | $13.43$42.14 |
| CRMD CorMedix Inc. Common Stock | $589.17M | 3.08 | $7.26 | ▼ 2.68% | $6.13$13.02 |
| ALT Altimmune Inc. Common Stock | $585.37M | — | $2.2 | ▼ 6.78% | $2.56$6.44 |
| CTNM Contineum Therapeutics Inc. Class A Common Stock | $577.48M | — | $7.08 | ▼ 10.38% | $7.96$17.79 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Nuvectis Pharma to Participate in the Maxim Growth Summit 2026Yahoo · 10/9/2026
- Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade GliomaYahoo · 9/24/2026
- HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $39 Price TargetBenzinga · 9/24/2026
- Nuvectis Pharma's NXP200 BRAF Inhibitor Receives China's Breakthrough Therapy DesignationBenzinga · 9/24/2026
- Nuvectis Pharma: Haisco Licensing Deal Revitalises Biotech - But No Rush To Invest TodaySeekingAlpha · 9/18/2026
Insider Activity
Insider Actions →- Carson Michael J. · August 3, 2026 · Grant30.0K
- Mosseri Marlio Charles · June 30, 2026 · Buy50.0K @ $18.32
- Ron Bentsur · June 30, 2026 · Buy12.5K @ $20
- Sanchez Juan · June 11, 2026 · Grant35.0K
- Kaplan Matthew L. · June 11, 2026 · Grant35.0K
- Hoberman Kenneth · June 11, 2026 · Grant35.0K
- Oliviero James F III · June 11, 2026 · Grant35.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 4.26M
- Total value held
- $32.84M
- Institutional holders
- 58
- Unknown764.4K
- Unknown659.9K
- Unknown651.8K
- Unknown407.1K
- Unknown384.1K
- Unknown378.6K
- Unknown166.5K
- Unknown124.2K
- Unknown105.3K
- Unknown78.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Nuvectis Pharma to speak at Maxim Growth Summit 2026
Nuvectis Pharma announced it will participate in the Maxim Growth Summit 2026. This corporate event provides an opportunity for the company to share updates with investors and analysts. Such appearances are standard for public companies seeking to maintain visibility in the market.
Nuvectis Pharma to speak at Maxim Growth Summit 2026. Nuvectis Pharma announced it will participate in the Maxim Growth Summit 2026. This corporate event provides an opportunity for the company to share updates with investors and analysts. Such appearances are standard for public companies seeking to maintain visibility in the market.